Area: Hematology
Location: Vienna, Australia
Date: June 11 to June 14
Description:
European Hematology Association
High risk CLL patients
Changing in the management of ITP
Novelties in the treatment of B cell lymphomas
Contemporary concepts and future perspectives in ALL
The treatment options of ALL
Perspectives on frontline therapy selection in patiens with CML-CP
Challenges for Global Standardization of BCR-ABL testing
The role of p53 pathway in CLL
Key issues in the treatment of lymphoma